SG11202108283QA - Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist - Google Patents

Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist

Info

Publication number
SG11202108283QA
SG11202108283QA SG11202108283QA SG11202108283QA SG11202108283QA SG 11202108283Q A SG11202108283Q A SG 11202108283QA SG 11202108283Q A SG11202108283Q A SG 11202108283QA SG 11202108283Q A SG11202108283Q A SG 11202108283QA SG 11202108283Q A SG11202108283Q A SG 11202108283QA
Authority
SG
Singapore
Prior art keywords
triazin
imidazo
amine derivatives
tlr7 agonist
tlr7
Prior art date
Application number
SG11202108283QA
Other languages
English (en)
Inventor
Guoliang Zhang
Jianzhuang Miao
Changyou Zhou
Gang Chen
Jing Li
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of SG11202108283QA publication Critical patent/SG11202108283QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202108283QA 2019-02-07 2020-02-06 Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist SG11202108283QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2019074732 2019-02-07
CN2019098757 2019-07-31
CN2020073673 2020-01-22
PCT/CN2020/074437 WO2020160711A1 (fr) 2019-02-07 2020-02-06 Dérivés d'imidazo[2,1-f] [1, 2, 4] triazin-4-amine utilisés en tant qu'agonistes de tlr7

Publications (1)

Publication Number Publication Date
SG11202108283QA true SG11202108283QA (en) 2021-08-30

Family

ID=71947004

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202108284TA SG11202108284TA (en) 2019-02-07 2020-02-06 Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist
SG11202108283QA SG11202108283QA (en) 2019-02-07 2020-02-06 Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11202108284TA SG11202108284TA (en) 2019-02-07 2020-02-06 Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist

Country Status (14)

Country Link
US (2) US20220119394A1 (fr)
EP (2) EP3921320B1 (fr)
JP (2) JP2022521473A (fr)
KR (2) KR20210125026A (fr)
CN (2) CN113423708A (fr)
AU (2) AU2020218383A1 (fr)
BR (2) BR112021015012A2 (fr)
CA (2) CA3129234A1 (fr)
IL (2) IL285315A (fr)
MX (2) MX2021009439A (fr)
SG (2) SG11202108284TA (fr)
TW (1) TWI835999B (fr)
WO (2) WO2020160711A1 (fr)
ZA (2) ZA202105339B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312291A (en) 2018-05-01 2024-06-01 Revolution Medicines Inc C-26-linked rapamycin analogs as MTOR inhibitors
CN112321590A (zh) * 2019-08-02 2021-02-05 百济神州有限公司 咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物作为tlr8激动剂
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
WO2022156678A1 (fr) * 2021-01-20 2022-07-28 上海维申医药有限公司 Agoniste de tlr7 macrocyclique, son procédé de préparation, composition pharmaceutique de celui-ci et son utilisation
JP2024513565A (ja) * 2021-04-09 2024-03-26 レヴォリューション・メディスンズ，インコーポレイテッド ラパマイシン類似体化合物の合成
CN118076585A (zh) * 2021-07-23 2024-05-24 国家医疗保健研究所 革兰氏阴性菌外排泵抑制剂
US20240108732A1 (en) * 2022-03-10 2024-04-04 Nammi Therapeutics, Inc. Formulated and/or Co-Formulated Lipid Nanocarriers Compositions Containing Toll-Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210891A1 (fr) * 2009-01-26 2010-07-28 Domain Therapeutics Nouveaux ligands du récepteur de l'adénosine et leurs utilisations
BRPI1008383A2 (pt) * 2009-02-11 2016-02-23 Univ California composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
KR101818779B1 (ko) * 2009-09-21 2018-01-15 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료용 ２'―플루오로 치환된 카바-뉴클레오사이드 유사체
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
WO2014035140A2 (fr) * 2012-08-30 2014-03-06 Kainos Medicine, Inc. Composés et compositions pour la modulation de l'activité histone méthyltransférase
CN112898308A (zh) * 2014-08-15 2021-06-04 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
EP3294737A4 (fr) * 2015-05-12 2018-10-03 Kalyra Pharmaceuticals, Inc. Composés bicycliques
TW201803871A (zh) * 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
US11084818B2 (en) * 2016-11-11 2021-08-10 Hepo Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use
JP2020520379A (ja) * 2017-05-18 2020-07-09 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． ヘテロアリール−ピラゾール誘導体ならびにその調製方法および医学的適用

Also Published As

Publication number Publication date
TW202045508A (zh) 2020-12-16
EP3921319B1 (fr) 2024-03-06
AU2020218383A1 (en) 2021-09-02
BR112021015012A2 (pt) 2021-10-05
US20230167117A1 (en) 2023-06-01
JP2022521473A (ja) 2022-04-08
MX2021009444A (es) 2021-11-12
BR112021015016A2 (pt) 2021-10-05
ZA202105339B (en) 2023-02-22
EP3921319A1 (fr) 2021-12-15
TW202045507A (zh) 2020-12-16
ZA202105338B (en) 2022-08-31
US20220119394A1 (en) 2022-04-21
SG11202108284TA (en) 2021-08-30
MX2021009439A (es) 2021-11-12
EP3921319A4 (fr) 2022-11-23
CN113454086A (zh) 2021-09-28
KR20210125026A (ko) 2021-10-15
EP3921320A1 (fr) 2021-12-15
CN113423708A (zh) 2021-09-21
WO2020160711A1 (fr) 2020-08-13
KR20210125025A (ko) 2021-10-15
EP3921320A4 (fr) 2022-11-09
IL285315A (en) 2021-09-30
IL285311A (en) 2021-09-30
CA3129234A1 (fr) 2020-08-13
CA3129178A1 (fr) 2020-08-13
WO2020160710A1 (fr) 2020-08-13
EP3921319C0 (fr) 2024-03-06
EP3921320B1 (fr) 2024-03-06
AU2020218872A1 (en) 2021-08-26
TWI835999B (zh) 2024-03-21
JP2022519374A (ja) 2022-03-23
EP3921320C0 (fr) 2024-03-06

Similar Documents

Publication Publication Date Title
IL285311A (en) Imidazo[1,2-f][4,2,1]triazine-4-amine derivatives as tlr7 agonists
HK1258157A1 (zh) 作為jak抑制劑的吡唑並[1，5-a]吡嗪-4-基衍生物
IL259004B (en) [4,2,1]triazolo[5,1-a]pyrimidin-7-yl compound
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
EP4008720A4 (fr) Dérivé d'imidazo[2,1-f][1,2,4]triazin-4-amine utilisé en tant qu'agoniste de tlr8
TWI800696B (zh) 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
IL290419B (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
IL272988A (en) Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors
HUE056561T2 (hu) Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
IL290445A (en) [4,2,1]triazolo[5,1-c]quinazoline-5-amines
ZA202100259B (en) Pyrrolo[1,2-b]pyridazine derivatives
IL280122A (en) Imidazo[2,1-B]pyridazine derivatives as TRK inhibitors
SG11202108648TA (en) 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative
IL279156A (en) History of hexahydropyrrolo[4,3-C]pyrrole useful as LOX inhibitors